M. Kudo

发表

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.

A. Gasbarrini, B. Sands, I. Lawrance, 2023, Gastroenterology.

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction.

J. Marrero, M. Kudo, R. Lencioni, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison between T1 relaxation time of Gd‐EOB‐DTPA‐enhanced MRI and liver stiffness measurement of ultrasound elastography in the evaluation of cirrhotic liver

M. Okada, T. Hyodo, Tatsuo Inoue, 2015, Journal of Magnetic Resonance Imaging.

Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel.

R. Finn, P. Chaudhury, N. Kokabi, 2024, Journal of vascular and interventional radiology : JVIR.

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

H. Kosaka, A. Soyama, Ying-Chun Shen, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

T. Crocenzi, Tae-You Kim, Y. Hotko, 2024, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.

J. Llovet, R. Finn, M. Yarchoan, 2024, Nature reviews. Clinical oncology.

Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma

Y. Minami, S. Hagiwara, T. Aoki, 2023, Cancers.

Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study

Y. Hiasa, A. Morishita, J. Tani, 2023, Hepatology research : the official journal of the Japan Society of Hepatology.

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy

Masatoshi Kudo, M. Kudo, 2023, Liver Cancer.

Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.

A. El-Khoueiry, S. Choo, J. Neely, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study

T. Ishikawa, K. Nouso, H. Toyoda, 2023, Journal of liver cancer.

Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study

V. Breder, B. Ryoo, Z. Ramji, 2024, Cancer.

Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study.

Y. Kondo, S. Shimose, T. Kagawa, 2024, Hepatology research : the official journal of the Japan Society of Hepatology.